3,5-二氟硫代苯甲酰胺 | 874791-10-3

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氟硫代苯甲酰胺
• 中文别名: 3,5-二氟硫代苯胺
• 英文名称: 3,5-Difluorothiobenzamide
• 英文别名: 3,5-difluorobenzenecarbothioamide
• CAS: 874791-10-3
• 化学式: C₇H₅F₂NS
• 分子量: 173.186
• InChiKey: UVKMTQYRQXSOOI-UHFFFAOYSA-N

物化性质

• 熔点：
  135-139℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1

反应信息

• 作为反应物：
  描述：

  3,5-二氟硫代苯甲酰胺 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 [2-(3,5-Difluorophenyl)-5-methyl-1,3-thiazol-4-yl]methanol
  参考文献：
  名称：

  Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography

  摘要：

  Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure activity relationship study was carried out Positron Emission Tomography (PET) using F-18-L-1-(2'-deoxy-2':-FluoroArabinofuranosyl) Cytosine (F-18-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = similar to 1-12 nM) using the F-18-L-FAC PET pharmacodynatnic assay identified compounds demonstrating superior in vivo efficacy.

  DOI：

  10.1021/jm400457y
• 作为产物：
  描述：

  3,5-二氟苯甲腈 在 吡啶 、 diammonium sulfide 、 三乙胺 作用下， 以 水 为溶剂， 反应 18.0h， 生成 3,5-二氟硫代苯甲酰胺
  参考文献：
  名称：

  Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography

  摘要：

  Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure activity relationship study was carried out Positron Emission Tomography (PET) using F-18-L-1-(2'-deoxy-2':-FluoroArabinofuranosyl) Cytosine (F-18-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = similar to 1-12 nM) using the F-18-L-FAC PET pharmacodynatnic assay identified compounds demonstrating superior in vivo efficacy.

  DOI：

  10.1021/jm400457y

文献信息

• [EN] HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS<br/>[FR] ACIDES HETEROARYLALCANOIQUES EN TANT QU'ANTAGONISTES DU RECEPTEUR D'INTEGRINE
  申请人：PHARMACIA CORP

  公开号：WO2004058254A1

  公开（公告）日：2004-07-15

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the ανβ3 and/or the ανβ5 integrin without significantly inhibiting the ανβ6 integrin.
• Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography
  作者：Jennifer M. Murphy、Amanda L. Armijo、Julian Nomme、Chi Hang Lee、Quentin A. Smith、Zheng Li、Dean O. Campbell、Hsiang-I Liao、David A. Nathanson、Wayne R. Austin、Jason T. Lee、Ryan Darvish、Liu Wei、Jue Wang、Ying Su、Robert Damoiseaux、Saman Sadeghi、Michael E. Phelps、Harvey R. Herschman、Johannes Czernin、Anastassia N. Alexandrova、Michael E. Jung、Arnon Lavie、Caius G. Radu

  DOI：10.1021/jm400457y

  日期：2013.9.12

  Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure activity relationship study was carried out Positron Emission Tomography (PET) using F-18-L-1-(2'-deoxy-2':-FluoroArabinofuranosyl) Cytosine (F-18-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = similar to 1-12 nM) using the F-18-L-FAC PET pharmacodynatnic assay identified compounds demonstrating superior in vivo efficacy.